Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07821450) titled 'Blepharoptosis After Repeated Intravitreal Anti-VEGF Injections: A Prospective Study' on Sept. 10.

Study Type: Observational

Primary Sponsor: Abdulkadir Kucuk

Condition: Blepharoptosis Age-Related Macular Degeneration Diabetic Macular Edema

Intervention: Other: Repeated intravitreal anti-VEGF injection with eyelid speculum

Recruitment Status: Not recruiting

Date of First Enrollment: September 25, 2026

Target Sample Size: 60

Countries of Recruitment: Turkey (Turkiye)

To know more, visit https://clinicaltrials.gov/study/NCT07821450

Published by HT Digital Content Services with permission from Health Daily...